Ruthenium-based chemotherapeutics: are they ready for prime time?
- 2.3k Downloads
Since the discovery of cis-platinum, many transition metal complexes have been synthesized and assayed for antineoplastic activity. In recent years, ruthenium-based molecules have emerged as promising antitumor and antimetastatic agents with potential uses in platinum-resistant tumors or as alternatives to platinum. Ruthenium compounds theoretically possess unique biochemical features allowing them to accumulate preferentially in neoplastic tissues and to convert to their active state only after entering tumor cells. Intriguingly, some ruthenium agents show significant activity against cancer metastases but have minimal effects on primary tumors. Two ruthenium-based drugs, NAMI-A and KP1019, have reached human clinical testing. This review will highlight the chemical properties, mechanism of action, preclinical data, and early phase clinical results of these two lead ruthenium compounds. Other promising ruthenium agents will also be reviewed with emphasis on the novel ruthenium compound ONCO4417, and DW1/2 that has demonstrated Pim-1 kinase inhibition in preclinical systems. Further development of these and other ruthenium agents may rely on novel approaches including rational combination strategies as well as identification of potential pharmacodynamic biomarkers of drug activity aiding early phase clinical studies.
KeywordsRuthenium Chemotherapy NAMI-A KP1019 ONCO4417
Conflict of interest statement
The authors indicate no financial or other conflicts of interest.
- 10.Schluga P, Hartinger CG, Egger A, Reisner E, Galanski M et al (2006) Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans 14:1796–1802Google Scholar
- 14.Sava G, Alessio E, Bergamo A, Mestroni G (1999) Sulfoxide ruthenium complexes. Top Biol Inorg Chem 1:143–169Google Scholar
- 15.Pieper T, Borsky K, Keppler BK (1999) Non-platinum antitumor compounds. Top Biol Inorg Chem 1:171–199Google Scholar
- 28.Mestroni G, Alessio E, Sava G (1998) International Patent PCT C 07F 15/00, A61 K 31/28, WO 98/0043Google Scholar
- 30.Zorzet S, Bergamo A, Cocchietto M, Sorc A, Gava B et al (2000) Lack of in vitro cytotoxicity, associated to increased G2-M cell fraction and inhibition of matrigel invasion, may predict in vivo-selective antimetastasis activity of ruthenium complexes. J Pharmacol Exp Ther 295:927–933PubMedGoogle Scholar
- 38.Brouwers EE, Tibben MM, Rosing H, Schellens JH, Beijnen JH (2007) Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry. Rapid Commun Mass Spectrom 21:1521–1530CrossRefPubMedGoogle Scholar
- 43.Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H et al (2006) From bench to bedside–preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J Inorg Biochem 100:891–904CrossRefPubMedGoogle Scholar
- 49.Hayward RL, Schornagel QC, Tente R, Macpherson JS, Aird RE et al (2005) Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175. Cancer Chemother Pharmacol 55:577–583CrossRefPubMedGoogle Scholar
- 50.Gaiddon C, Jeannequin P, Bischoff P, Pfeffer M, Sirlin C et al (2005) Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. J Pharmacol Exp Ther 315:1403–1411CrossRefPubMedGoogle Scholar
- 52.Foster RE, Cole DA, Mead S, Sadler PJ, Grimshaw KM (2009) Investigation into the mechanism of action of the ruthenium(II) organometallic complex, ONCO 4417. In: Proceedings of the American association for cancer research, April 18–22: Abstract 889Google Scholar
- 56.Scolaro C, Chaplin AB, Hartinger CG, Bergamo A, Cocchietto M et al. (2007) Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Trans 43:5065–5072Google Scholar
- 58.Schäfer S, Ott I, Gust R, Sheldrick WS (2007) Influence of the polypyridyl (pp) ligand size on the DNA binding properties, cytotoxicity and cellular uptake of organoruthenium(II) complexes of the type [(η6-C6Me6)Ru(L)(pp)]n+ [L = Cl, n = 1; L = (NH2)2CS, n = 2]. Eur J Inorg Chem 19:3034–3046Google Scholar
- 59.Schatzschneider U, Niesel J, Ott I, Gust R, Alborzinia H et al (2008) Cellular uptake, cytotoxicity, and metabolic profiling of human cancer cells treated with ruthenium(II) polypyridyl complexes [Ru(bpy)2(N–N)]Cl2 with N–N = bpy, phen, dpq, dppz, and dppn. Chem Med Chem 3:1104–1109PubMedGoogle Scholar
- 60.Meggers E, Atilla-Gokcumen GE, Bregman H, Maksimoska J, Mulcahy SP et al (2007) Exploring chemical space with organometallics: ruthenium complexes as protein kinase inhibitors. Synlett 8:1177–1189Google Scholar
- 65.US Department of Health and Human Services Food and Drug Administration (2004) Innovation or stagnation: challenges and opportunity on the critical path to new medical products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html [last accessed 02/05/2010]